DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/2hlmhs/anterior) has announced the addition of the “Anterior Uveitis-Pipeline Insights” report to their offering. Anterior Uveitis- Pipeline Insights provides the…
Second Sight Medical Products reported total revenue of $2.7 million in the second quarter, a 335% increase compared with $611,000 in the same quarter of 2014.The increase in revenue was attributed to a higher number of implanted Argus II retinal prost…
LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced the completion of patient enrollment in its U.S. Food and Drug Administration (FDA) pivotal Investigational Device Exemption (IDE) trial for the iStent inject® Trabecular Micro-Bypass Stent. The iStent inject relies on a similar fl
IRVINE, Calif., BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) today announced that Vicente Anido, Jr., Ph.D., Chief Executive Officer and Chairman of the Board, will present at the Canaccord Genuity Growth Conference on Wednesday, August 12, 2015 at 12:30 p.m. Eastern Time in Boston, MA. Dr. Anido’s presentation will include an Aerie overview and business update. The presentation will be webcast live and may be accessed by visiting A
Scientists at the University of York have shed new light on how humans process colour – revealing that we see things differently in winter compared with summer.
Eye examination frequency is not optimal among US adults with diabetes at risk for retinal damage, according to recent National Health Interview Survey data. Medscape Medical News